PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


# TRANSMITTAL FORM

*(to be used for all correspondence after initial filing)*

| | | | |
|---|---|---|---|
| | | Application Number | 10/617,616 |
| | | Filing Date | July 11, 2003 |
| | | First Named Inventor | Bore G. RAJU |
| | | Art Unit | Not Yet Assigned |
| | | Examiner Name | Not Yet Assigned |
| Total Number of Pages in This Submission | 40 pages + 145 references | Attorney Docket Number | 342312004800 |

## ENCLOSURES (*Check all that apply*)

- [ ] Fee Transmittal Form
  - [ ] Fee Attached
- [ ] Amendment/Reply
  - [ ] After Final
  - [ ] Affidavits/declaration(s)
- [ ] Extension of Time Request
- [ ] Express Abandonment Request
- [x] Information Disclosure Statement (3 pages)
- [ ] Certified Copy of Priority Document(s)
- [ ] Response to Missing Parts/ Incomplete Application
  - [ ] Response to Missing Parts under 37 CFR 1.52 or 1.53
- [ ] Drawing(s)
- [ ] Licensing-related Papers
- [ ] Petition
- [ ] Petition to Convert to a Provisional Application
- [ ] Power of Attorney, Revocation Change of Correspondence Address
- [ ] Terminal Disclaimer
- [ ] Request for Refund
- [ ] CD, Number of CD(s) _____
- [ ] After Allowance Communication to Group
- [ ] Appeal Communication to Board of Appeals and Interferences
- [ ] Appeal Communication to Group **(Appeal Notice, Brief, Reply Brief)**
- [ ] Proprietary Information
- [ ] Status Letter
- [x] Other Enclosure(s) (please identify below):
  - Form PTO-1449 (original + 3 copy (36 pages total))
  - 145 References (divided into 15 Volumes each volume containing a coversheet (sent in 3 separate boxes))
  - Return Receipt Postcard

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|---|---|
| Firm or Individual name | MORRISON & FOERSTER LLP (Customer No. 25226)<br>Nicholas S. Buffinger - 39,124 |
| Signature | |
| Date | March 8, 2004 |

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 3/8/04 Signature: _____ (Mei Y. Leung)

PATENT
Docket No. 342312004800

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on March 8, 2004.

Mei Y. Leung

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Bore G. RAJU et al.

Serial No.: 10/617,616

Filing Date: July 11, 2003

For: N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Pursuant to the USPTO notice dated July 11, 2003, waiving the requirement under 37 C.F.R. § 1.98 (a)(2)(i) to provide copies of U.S. Patents and U.S. Published Applications, copies of those references are

not submitted. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

☐ With the application; accordingly, no fee or separate requirements are required.

☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.

☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.

☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.

- ☐ A fee is required. A check in the amount of __ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.

☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.

- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 342312004800. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 8, 2004

Respectfully submitted,

By: _____

Nicholas S. Buffinger
Registration No. 39,124

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5816
Facsimile: (650) 494-0792

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

*(Use several sheets if necessary)*

| Docket Number 342312004800 | Application Number 10/617,616 |
|---|---|
| Applicant: Bore G. RAJU et al | |
| Filing Date July 11, 2003 | Group Art Unit Not Yet Assigned |
| Mailing Date March 8, 2004 | |



## U.S. PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Filing Date If Appropriate |
|---|---|---|---|---|---|---|---|
| | 1. | 01/24/2002 | 2002/0010199 | Hagmann et al. | | | |
| | 2. | 02/14/2002 | 2002/0019419 | De Laszlo et al. | | | |
| | 3. | 05/30/2002 | 2002/0065391 | Stilz et al. | | | |
| | 4. | 10/03/2002 | 2002/0143043 | Wehner et al. | | | |
| | 5. | 03/06/2003 | 2003/0045555 | Rivera et al. | | | |
| | 6. | 07/20/1999 | 5,925,659 | Patchett et al. | | | |
| | 7. | 02/01/2000 | 6,020,347 | DeLaszlo et al. | | | |
| | 8. | 02/20/2001 | 6,191,171 | DeLaszlo et al. | | | |
| | 9. | 01/22/2002 | 6,340,678 | Matsuhisa et al. | | | |
| | 10. | 03/05/2002 | 6,353,099 | DeLaszlo et al. | | | |
| | 11. | 06/18/2002 | 6,407,065 | Wattanasin et al. | | | |
| | 12. | 07/16/2002 | 6,420,418 | Hagmann et al. | | | |
| | 13. | 08/13/2002 | 6,432,923 | Wattanasin et al. | | | |
| | 14. | 10/15/2002 | 6,465,513 | Grant et al. | | | |
| | 15. | 12/10/2002 | 6,492,421 | Thorsett el al. | | | |
| | 16. | 09/30/2003 | 6,627,634 | Himmelsbach et al. | | | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials | Ref. No. | Date | Document No. | Country | Class | Subclass | Translation YES | Translation NO |
|---|---|---|---|---|---|---|---|---|
| | 17. | 01/02/1992 | EP 0 463 596 | Europe | | | | |
| | 18. | 12/30/1992 | EP 0 520 336 | Europe | | | | |
| | 19. | 02/02/2000 | EP 0 976 722 | Europe | | | | |
| | 20. | 11/02/2000 | EP 1 048 652 | Europe | | | | |
| | 21. | 04/18/1996 | WO 96/10999 | WIPO | | | | |
| | 22. | 05/23/1996 | WO 96/15148 | WIPO | | | | |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| Form PTO-1449<br>INFORMATION DISCLOSURE CITATION IN AN APPLICATION<br>*(Use several sheets if necessary)* | Docket Number 342312004800 | Application Number 10/617,616 |
|---|---|---|
| | Applicant<br>Bore G. RAJU et al | |
| | Filing Date July 11, 2003 | Group Art Unit Not Yet Assigned |
| | Mailing Date March 8, 2004 | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | 23. | 09/26/1996 | WO 96/29309 | WIPO | | | | |
| | 24. | 12/05/1996 | WO 96/38471 | WIPO | | | | |
| | 25. | 05/29/1997 | WO 97/18837 | WIPO | | | | |
| | 26. | 11/06/1997 | WO 97/41102 | WIPO | | | | |
| | 27. | 11/13/1997 | WO 97/42179 | WIPO | | | | |
| | 28. | 04/23/1998 | WO 98/16512 | WIPO | | | Abstract | |
| | 29. | 07/23/1998 | WO 98/31661 | WIPO | | | Abstract | |
| | 30. | 09/11/1998 | WO 98/39303 | WIPO | | | | |
| | 31. | 09/11/1998 | WO 98/39325 | WIPO | | | Abstract | |
| | 32. | 03/11/1999 | WO 99/11258 | WIPO | | | | |
| | 33. | 05/27/1999 | WO 99/25685 | WIPO | | | | |
| | 34. | 06/03/1999 | WO 99/26923 | WIPO | | | | |
| | 35. | 07/08/1999 | WO 99/33805 | WIPO | | | Abstract | |
| | 36. | 10/21/1999 | WO 99/52926 | WIPO | | | | |
| | 37. | 12/16/1999 | WO 99/63937 | WIPO | | | | |
| | 38. | 12/29/1999 | WO 99/67230 | WIPO | | | | |
| | 39. | 04/20/2000 | WO 00/21920 | WIPO | | | | |
| | 40. | 07/06/2000 | WO 00/39081 | WIPO | | | | |
| | 41. | 07/27/2000 | WO 00/43371 | WIPO | | | | |
| | 42. | 08/31/2000 | WO 00/50396 | WIPO | | | | |
| | 43. | 10/12/2000 | WO 00/59878 | WIPO | | | | |
| | 44. | 10/12/2000 | WO 00/59880 | WIPO | | | | |
| | 45. | 10/12/2000 | WO 00/60355 | WIPO | | | | |
| | 46. | 01/04/2001 | WO 01/00616 | WIPO | | | Abstract | |
| | 47. | 02/01/2001 | WO 01/06984 | WIPO | | | | |
| | 48. | 02/01/2001 | WO 01/07044 | WIPO | | | | |
| | 49. | 02/01/2001 | WO 01/07048 | WIPO | | | | |
| | 50. | 02/01/2001 | WO 01/07052 | WIPO | | | | |
| | 51. | 02/22/2001 | WO 01/12183 | WIPO | | | | |
| | 52. | 03/01/2001 | WO 01/14328 | WIPO | | | | |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| Form PTO-1449<br>INFORMATION DISCLOSURE CITATION IN AN APPLICATION<br>*(Use several sheets if necessary)* | Docket Number 342312004800 | Application Number 10/617,616 |
|---|---|---|
| | Applicant<br>Bore G. RAJU et al | |
| | Filing Date July 11, 2003 | Group Art Unit Not Yet Assigned |
| | Mailing Date March 8, 2004 | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | 53. | 03/08/2001 | WO 01/15733 | WIPO | | | | |
| | 54. | 04/05/2001 | WO 01/23376 | WIPO | | | | |
| | 55. | 05/03/2001 | WO 01/30781 | WIPO | | | | |
| | 56. | 09/27/2001 | WO 01/70708 | WIPO | | | | |
| | 57. | 10/18/2001 | WO 01/77104 | WIPO | | | Abstract | |
| | 58. | 12/06/2001 | WO 01/92253 | WIPO | | | | |
| | 59. | 01/10/2002 | WO 02/02522 | WIPO | | | | |
| | 60. | 01/31/2002 | WO 02/08202 | WIPO | | | | |
| | 61. | 01/31/2002 | WO 02/08206 | WIPO | | | | |
| | 62. | 01/31/2002 | WO 02/08222 | WIPO | | | | |
| | 63. | 08/22/2002 | WO 02/064558 | WIPO | | | | |
| | 64. | 01/16/2003 | WO 03/004460 | WIPO | | | | |
| | 65. | 01/30/2003 | WO 03/007949 | WIPO | | | | |
| | 66. | 01/30/2003 | WO 03/008380 | WIPO | | | Abstract | |
| | 67. | 02/13/2003 | WO 03/011288 | WIPO | | | | |

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

| Examiner Initials | Ref. No. | Title |
|---|---|---|
| | 68. | Anderson, M.S. et al. (1993) "UDP-*N*-acetylglucosamine Acyltransferase of *Escherichia coli*," *J. Biol. Chem.* 268(26):19858-19865. |
| | 69. | Archibald, S.C. et al. (2000). "Discovery and Evaluation of Potent, Tyrosine-based $\alpha 4\beta 1$ Integrin Antagonists," *Bioorganic & Medicinal Chemistry Letters* 10:997-999. |
| | 70. | Astles, P.C. et al. (2001). "Diamine Containing VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry* 9:2195-2202. |
| | 71. | Azzolina, B.A. et al. (2001) "The Cell Wall and Cell Division Gene Cluster in the *Mra* Operon of *Pseudomonas aeruginosa*: Cloning, Production, and Purification of Active Enzymes," *Protein Expression and Purification* 21(3): 393-400. |
| | 72. | Batt, D.G. (2000). "Disubstituted Indazoles as Potent Antagonists of the Integrin $\alpha_v\beta_3$," *J. Med. Chem.* 43:41-58. |
| | 73. | Belvisi, L. et al. (2001). "Potent Integrin Antagonists from a Small Library of RGD-Including Cyclic Pseudopeptides," *Organic Letters* 3(7):1001-1004. |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| Form PTO-1449<br>INFORMATION DISCLOSURE CITATION IN AN APPLICATION<br>*(Use several sheets if necessary)* | Docket Number 342312004800 | Application Number 10/617,616 |
|---|---|---|
| | Applicant<br>Bore G. RAJU et al | |
| | Filing Date July 11, 2003 | Group Art Unit Not Yet Assigned |
| | Mailing Date March 8, 2004 | |


| | | |
|---|---|---|
| | 74. | Bianchi, E. et al. (2000). "Integrin LFA-1 Interacts with the Transcriptional Co-Activator JAB1 to Modulate AP-1 Activity," *Nature* 404:617-621. |
| | 75. | Blythin, D.J. et al. (1994). "Synthesis of Racemic *cis*- and *trans*-3-Phenylazetidine-2-Carboxylic Acids as Conformationally Restricted Analogs of Phenylalanine," *J. Org. Chem.* 59:6098-6100. |
| | 76. | Boer, J. et al. (2001). "Design and Synthesis of Potent and Selective α4β7 Integrin Antagonists," *J. Med. Chem.* 44(16):2586-2592. |
| | 77. | Chang, L.L. et al. (2002). "The Discovery of Small Molecule Carbamates as Potent Dual $\alpha_4\beta_1/\alpha_4\beta_7$ Integrin Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:159-163. |
| | 78. | Chen, L. et al. (2000). "*N*-Acyl Phenylalanine Analogues as Potent Small Molecule VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 10:725-727. |
| | 79. | Chen, L. et al. (2000). "*N*-Benzylpyroglutamyl-L-phenylalanine Derivatives as VCAM/VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 10:729-733. |
| | 80. | Chen, L. et al. (2002). "Focused Library Approach for Identification of New *N*-Acylphenylalanines as VCAM/VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:1679-1682. |
| | 81. | Chen, L. et al. (2002). "*N*-Acyl-L-phenylalanine Derivatives as Potent VLA-4 Antagonists that Mimic a Cyclic Peptide Conformation," *Bioorganic & Medicinal Chemistry Letters* 12:137-140. |
| | 82. | Chen, M-H. et al. (1999). "Carbohydroxamido-Oxazolidines: Antibacterial Agents That Target Lipid A Biosynthesis," *Bioorg. & Med. Chem. Letts.* 9(3):313-318. |
| | 83. | Clements, J.M. et al. (2002). "Antibacterial Activities and Characterization of Novel Inhibitors of LpxC," *Antimicrobial Agents and Chemotherapy.* 46(6):1793-1799. |
| | 84. | Cromwell, N.H. et al. (1979). "The Azetidines. Recent Synthetic Developments." *Chemical Reviews* 79(4): 331-358. |
| | 85. | de Laszlo, S.E. et al. (2002). "Identification of Unique VLA-4 Antagonists from a Combinatorial Library," *Bioorganic & Medicinal Chemistry Letters* 12:685-688. |
| | 86. | Doherty, G.A. et al. (2002). "*N*-Aryl 2,6-Dimethozybiphenylalanine Analogues as VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:729-731. |
| | 87. | Doherty, G.A. et al. (2002). "Substituted Tetrahydrofuroyl-1-phenylalanine Derivatives as Potent and Specific VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:1501-1505. |
| | 88. | Dubree, N.J.P. et al. (2002). "Selective α4β7 Integrin Antagonists and Their Potential as Antiinflammatory Agents," *J. Med. Chem.* 45(16):3451-3457. |
| | 89. | Duggan, M.E. et al. (2000). "Nonpeptide $\alpha_v\beta_3$ Antagonists. 1. Transformation of a Potent, Integrin-Selective $\alpha_{IIb}\beta_3$ Antagonist into a Potent $\alpha_v\beta_3$ Antagonist," *J. Med. Chem.* 43:3736-3745. |
| | 90. | Feuston, B.P. (2002). "Binding Model for Nonpeptide Antagonists of $\alpha_v\beta_3$ Integrin," *Journal of Medicinal Chemistry* 45(26):5640-5648. |


| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| Form PTO-1449<br>INFORMATION DISCLOSURE CITATION IN AN APPLICATION<br>*(Use several sheets if necessary)* | Docket Number 342312004800 | Application Number 10/617,616 |
|---|---|---|
| | Applicant<br>Bore G. RAJU et al | |
| | Filing Date July 11, 2003 | Group Art Unit Not Yet Assigned |
| | Mailing Date March 8, 2004 | |


| | | |
|---|---|---|
| | 91. | Fotouhi, N. et al. (2000). "Cyclic Thioether Peptide Mimetics as VCAM-VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 10:1167-1169. |
| | 92. | Fotouhi, N. et al. (2000). "The Design and Synthesis of Potent Cyclic Peptide VCAM-VLA-4 Antagonists Incorporating an Achiral Asp-Pro Mimetic," *Bioorganic & Medicinal Chemistry Letters* 10:1171-1173. |
| | 93. | Gadek, T.R. et al. (2002). "Generation of an LFA-1 Antagonist by the Transfer of the ICAM-1 Immunoregulatory Epitope to a Small Molecule," *Science* 295:1086-1089. |
| | 94. | Goodman, S.L. et al. (2002). "Nanomolar Small Molecule Inhibitors for $\alpha v\beta 6$, $\alpha v\beta 5$, and $\alpha v\beta 3$ Integrins," *J. Med. Chem.* 45(5):1045-1051. |
| | 95. | Hagmann, W.K. et al. (2001). "The Discovery of Sulfonylated Dipeptides as Potent VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 11:2709-2713. |
| | 96. | Huth, J.R. et al. (2000). "NMR and Mutagenesis Evidence for an I Domain Allosteric Site That Regulates Lymphocyte Function-Associated Antigen 1 Ligand Binding," *PNAS* 97(10):5231-5236. |
| | 97. | Hyland, S.A. et al. (1997). "Cloning, Expression, and Purification of UDP-3-O-Acyl-GlcNAc Deacetylase from *Pseudomonas aeruginosa*: A Metalloamidase of the Lipid A Biosynthesis Pathway," *J. Bacteriology* 179(6): 2029-2037. |
| | 98. | Inagawa, T. et al. (2001). "Defective Plasmid Partition in *ftsH* Mutants of *Escherichia coli*," *Mol. Genet. Genomics* 265(5):755-762. |
| | 99. | Jackman, J.E. (1999). "Metal Ion Requirement and Inhibition of the UDP-3-*O*-acyl-GlcNAc Deacetylases of *Escherichia coli* and *Aquifex Aeolicus*," *Dissertation Department of Biochemistry, Duke University* 203 pages. |
| | 100. | Jackman, J.E. et al. (1999). "UDP-3-*O*-(*R*-3-Hydroxymyristoyl)-*N*-acetylgucosamine Deacetylase of *Escherichia coli* Is a Zinc Metalloenzyme," *Biochemistry* 38(6):1902-1911. |
| | 101. | Jackman, J.E. et al. (2000). "Antibacterial Agents that Target Lipid A Biosynthesis in Gram-Negative Bacteria: Inhibition of Diverse UDP-3-*O*-(*R*-3-hydroxymyristoyl)-*N*-acetylglucosamine Deacetylases by Substrate Analogs Containing ZincBinding Motifs," *J. Biol. Chem.* 275(15):11002-11009. |
| | 102. | Jackman, J.E. et al. (2001). "Site-Directed mutagenesis of the Bacterial Metalloamidase UDP-3-*O*-acyl)-*N*-acetylglucosamine Deacetylase (LpxC). Identification of the Zinc Binding Site," *Biochemistry* 40: 514-523. |
| | 103. | Kamenecka, T.M. et al. (2002). "*N*-Aryl-prolyl-dipeptides as Potent Antagonists of VLA-4," *Bioorganic & Medicinal Chemistry Letters* 12:2205-2208. |
| | 104. | Kelly, T.A. et al. (1999). "Cutting Edge: A Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion," *The Journal of Immunology* 163:5173-5177. |
| | 105. | Kline, T. et al. (2001). "Potent, Novel in Vitro Inhibitors of the *Pseudomonas aeruginosa* Deacetylast LpxC," *J. Med. Chem.* 45(14):3112-3129. |


| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| Form PTO-1449<br>INFORMATION DISCLOSURE CITATION IN AN APPLICATION<br>*(Use several sheets if necessary)* | Docket Number 342312004800 | Application Number 10/617,616 |
|---|---|---|
| | Applicant<br>Bore G. RAJU et al | |
| | Filing Date July 11, 2003 | Group Art Unit Not Yet Assigned |
| | Mailing Date March 8, 2004 | |

| | | |
|---|---|---|
| | 106. | Kloser, A. et al. (1998) "Modulations in Lipid A and Phospholipid Biosynthesis Pathways Influence Outer Membrane Protein Assembly in *Escherichia coli* K-12," *Mol. Microbiol.* 27(5):1003-1008. |
| | 107. | Kloser, A.W. et al. (1996). "*asmB*, a Suppressor Locus for Assembly-Defective OmpF Mutants of *Escherichia coli*, Is Allelic to *envA* (*IpxC*)," *J. Bacteriol.* 178(17):5138-5143. |
| | 108. | Kobayashi, T. et al. (2002). "Convenient Synthesis of 3,3,3-Trifluoropropenyl Compounds from Aromatic Aldehydes by Means of the TBAF-Mediated Horner Reaction," *J. Org. Chem.* 67(9):3156-3159. |
| | 109. | Kopka, I.E. et al. (2002). "Substituted 3-Amino Biaryl Propionic Acids as Potent VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:2415-2418. |
| | 110. | Kopka, I.E. et al. (2002). "Substituted *N*-(3,5-Dichlorobenzenesulfonyl)-L-prolyl-phenylalanine Analogues as Potent VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:637-640. |
| | 111. | Lee, K-H. et al. (2002). "T Cell Receptor Signaling Precedes Immunological Synpase Formation," *Science* 295:1539-1542. |
| | 112. | Li, B. et al. (2002). "*N*-(Arylacetyl)-biphenylalanines as Potent VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:2141-2144. |
| | 113. | Li, X. et al. (2002). "Synthesis of a Carbohydrate-Derived Hydroxamic Acid Inhibitor of the Bacterial Enzyme (LpxC) Involved in Lipid A Biosynthesis," *Org. Lett.* 5(4):539-541. |
| | 114. | Lin, K-C. et al. (1998). "Very Late Antigen 4 (VLA4) Antagonists as Anti-Inflammatory Agents," *Current Opinion in Chemical Biology* 2:453-457. |
| | 115. | Lin, K-C. et al. (1999). "Selective, Tight-Binding Inhibitors of Integrin $\alpha 4\beta 1$ That Inhibit Allergic Airway Responses," *J. Med. Chem.* 42:920-934. |
| | 116. | Lin, L.S. et al. (2002). "The Discovery of Acylated $\beta$-Amino Acids as Potent and Orally Bioavailable VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:611-614. |
| | 117. | Link, J.T. et al. (2001). "Discovery and SAR of Diarylsulfide Cyclopropylamide LFA-1/ICAM-1 Interaction Antagonist," *Bioorganic & Medicinal Chemistry Letters* 11:973-976. |
| | 118. | Liu, G. et al. (2000). "Discovery of Novel *p*-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 1. Identification of an Additional Binding Pocket Based on an Anilino Diaryl Sulfide Lead," *J. Med. Chem.* 43:4025-4040. |
| | 119. | Liu, G. et al. (2001). "Novel *p*-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intracellular Adhesion Molecule-1 Interaction. 2. Mechanism of Inhibition and Structure-Based Improvement of Pharmaceutical Properties," *J. Med. Chem.* 44:1202-1210. |
| | 120. | Lu, T.T. et al. (2002). "Integrin-Mediated Long-Term B Cell Retention in the Splenic Marginal Zone," *Science* 297:409-412. |
| | 121. | Mousa, S.A. (2002). "Vitronectin Receptors in Vascular Disorders," *Current Opinion in Investigational Drugs* 3(8):1191-1195. |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| Form PTO-1449<br>INFORMATION DISCLOSURE CITATION IN AN APPLICATION<br>*(Use several sheets if necessary)* | Docket Number 342312004800 | Application Number 10/617,616 |
|---|---|---|
| | Applicant<br>Bore G. RAJU et al | |
| | Filing Date July 11, 2003 | Group Art Unit Not Yet Assigned |
| | Mailing Date March 8, 2004 | |

| | | |
|---|---|---|
| | 122. | Müller, G. et al. (2001). "Discovery and Evaluation of Piperidinyl Carboxylic Acid Derivatives as Potent $\alpha_4\beta_1$ Integrin Antagonists," *Bioorganic & Medicinal Chemistry Letters* 11:3019-3021. |
| | 123. | Ogura, T. et al. (1999). "Balanced Biosynthesis of Major Membrane Components Through Regulated Degradation of the Committed Enzyme of Lipid A Biosynthesis by the AAA Protease FtsH (HflB) in *Escherichia coli*," *Mol. Microbiol.* 31(3):833-844. |
| | 124. | Ohta, N. et al. (1999). "The Organellar Genomes of *Cyanidioschyzon merolae*," *In* Enigmatic Microorganisms and Life In Extreme Environments, Seckbach, J. ed., Kluwer Academic Publishers: The Netherlands 1:141-149. |
| | 125. | Onishi, H.R. et al. (1996). "Antibacterial Agents That Inhibit Lipid A Biosynthesis," *Science* 274:980-982. |
| | 126. | Pei, Z. et al. (2001). "Discovery of Potent Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 3. Amide (C-Ring) Structure-Activity Relationship and Improvement of Overall Properties of Arylthio Cinnamides," *J. Med. Chem.* 44:2913-2920. |
| | 127. | Pepinsky, R.B. et al. (2002). "Comparative Assessment of the Ligand and Metal Ion Binding Properties of Integrins $\alpha 9\beta 1$ and $\alpha 4\beta 1$," *Biochemistry* 41:7125-7141. |
| | 128. | Pirrung, M.C. et al. (2002). "Inhibition of the Antibacterial Target UDP-(3-*O*-acyl)-*N*-acetylglucosamine Deacetylease (LpxC): Isoxazoline Zinc Amidase Inhibitors Bearing Diverse Metal Binding Groups," *J. Med. Chem.* 45(19):4359-4370. |
| | 129. | Pirrung, M.C. et al. (2003). "High-Throughput Catch-and-Release Synthesis of Oxazoline Hydroxamates. Structure-Activity of *Escherichia coli* LpxC: In Vitro Enzyme Inhibition and Antibacterial Properties," *J. Am. Chem. Soc.* 125: 1575-1586. |
| | 130. | Pitts, W.J. et al. (2000). "Isoxazolines as Potent Antagonists of the Integrin $\alpha_v\beta_3$ ," *J. Med. Chem.* 43:27-40. |
| | 131. | Porter, J.R et al. (2002). "*N*-(Pyrimidin-4-yl) and *N*-(Pyridin-2-yl) Phenylalanine Derivatives as VLA-4 Integrin Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:1595-1598. |
| | 132. | Porter, J.R. et al. (2002). "Squaric Acid Derivatives as VLA-4 Integrin Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:1051-1054. |
| | 133. | Porter, J.R. et al. (2003). "Dehydrophenylalanine Derivatives as VLA-4 Integrin Antagonists," *Bioorganic & Medicinal Chemistry Letters* 13:805-808. |
| | 134. | Price, N.P. et al. (1994). "Biosynthesis of a Structurally Novel Lipid A in *Rhizobium leguminosarum*: Identification and Characterization of Six Metabolic Steps Leading From UDP-GlcNAc to 3-Deoxy-D-*manno*-2-Octulosonic $Acid_2$-Lipid $IV_A$," *J. Bacteriol.* 176(15):4646-4655. |
| | 135. | Qiu, X-L. et al. (2000). "Practical Synthesis of Boc-Protected *cis*-4-Trifluoromethyl and *cis*-4-Difluoromethyl-L- prolines," *J. Org. Chem.* 67:7162-7164. |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| Form PTO-1449<br>INFORMATION DISCLOSURE CITATION IN AN APPLICATION<br>*(Use several sheets if necessary)* | Docket Number 342312004800 | Application Number 10/617,616 |
|---|---|---|
| | Applicant<br>Bore G. RAJU et al | |
| | Filing Date July 11, 2003 | Group Art Unit Not Yet Assigned |
| | Mailing Date March 8, 2004 | |

| | | |
|---|---|---|
| | 136. | Raetz, C.R.H. (1998). "Enzymes of Lipid A Biosynthesis: Targets for the Design of New Antibiotics," *In* Endotoxins and Sepsis: Molecular Mechanisms of Pathogenesis, Host Resistances, and Therapy J. Levin et al. eds., Wiley-Liss: New York, NY pp. 1-14. |
| | 137. | Raetz. C.R.H. (1996). "Bacterial Lipopolysaccharides: A Remarkable Family of Bioactive Macroamphiphiles" Chapter 69 In *Escherichia coli* and *Salmonella*: Cellular and Molecular Biology Second Edition, Neidhardt, F.C. ed., ASM Press: Materials Park, OH Vol. I, pp. 1035-1063. |
| | 138. | Rodebaugh, R.M. et al. (1971)."2-Carboazetidine Derivatives (1)," *J. Heterocycl. Chem.* 8:19-24. |
| | 139. | Scozzafava, A. et al. (2002). "Carbonic Anhydrase Activators: High Affinity Isozymes I, II, and IV Activators, Incorporating a $\beta$-Alanyl-Histidine Scaffold," *J. Med. Chem.* 45(2):284-291. |
| | 140. | Sekikawa, I. et al. (1983). "Synthesis of Isonipecotinoyl Analogues of Aminopterin and Folic Acid," *J. Heterocyclic Chem.* 20:807-809. |
| | 141. | Sidduri, A. et al. (2002). "*N*-Aroyl-L-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:2479-2482. |
| | 142. | Sidduri, A. et al. (2002). "*N*-Cycloalkanoyl-L-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:2475-2478. |
| | 143. | Singh, J. et al. (2002). "Identification of Potent and Novel $\alpha 4\beta 1$ Antagonists Using in Silico Screening," *J. Med. Chem.* 45:2988-2993. |
| | 144. | Sorensen, P.G. et al. (1996). "Regulation of USP-3-*O*-(*R*-3-hydroxymyristoyl)-*N*-acetylglucosamine Deacetylase in *Escherichia coli*. The Second Enzymatic Step of Lipid A Biosynthesis," *J. Biol. Chem.* 271(42):25898-25905. |
| | 145. | Su, T. et al. (1997). "Fibrinogen Receptor (GPIIb-IIIa) Antagonists Derived from 5,6-Bicyclic Templates. Amidinoindoles, Amidinoindazoles, and Amidinobenzofurans Containing the *N*-$\alpha$-Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors," *J. Med. Chem.* 40:4308-4318. |
| | 146. | Sutherland, P.J. et al. (1998) "*Dictyostelium discoideum* Fatty-acyl Amidase II Has Deacylase Activity on *Rhizobium* Nodulation Factors," *J. Biol. Chem.* 273(8):4459-4464. |
| | 147. | Tilley, J. et al. (2000). "Carbacyclic Peptide Mimetics as VCAM-VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 10:1163-1165. |
| | 148. | Tilley, J.W. et al. (2001). "Imide and Lactam Derivatives of *N*-Benzylpyroglutamyl-L-phenylalanine as VCAM/VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 11:1-4. |
| | 149. | Tumey, L.N. et al. (2001). "Parallel Synthesis of Lipid A Biosynthesis Inhibitors," *Abstracts of Papers, Part 2: 222nd ACS National Meeting*: Chicago, IL, August 26-30, 2001. Abstract No. 623, one page. |
| | 150. | Vaara, M. (1996). "Lipid A: Target for Antibacterial Drugs," *Science* 274: 939-940. |
| | 151. | van der Merwe, P.A. et al. (2002). "The Immunological Synapse - a Multitasking System," *Science* 295:1479-1480. |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

| Form PTO-1449<br>INFORMATION DISCLOSURE CITATION IN AN APPLICATION<br>*(Use several sheets if necessary)* | Docket Number 342312004800 | Application Number 10/617,616 |
|---|---|---|
| | Applicant<br>Bore G. RAJU et al | |
| | Filing Date July 11, 2003 | Group Art Unit Not Yet Assigned |
| | Mailing Date March 8, 2004 | |

| | | |
|---|---|---|
| | 152. | Wang et al. (2001). "A Fluorescence-Based Homogeneous Assay for Measuring Activity of UDP-3-*O*-(*R*-3-Hydroxymyristoyl)-*N*-acetylglucosamine Deacetylase." *Analytical Biochem.* 290: 338-346. |
| | 153. | Wattanasin, S. et al. (2001). "Design and Synthesis of Potent and Selective Inhibitors of Integrin VLA-4," *Bioorganic & Medicinal Chemistry Letters* 11:2955-2958. |
| | 154. | Wehner, V. et al. (2002). "Aromatic β-Amino Acids as Asp-Phg Mimics in LDV Derived VLA-4 Antagonists," *Synthesis* 14:2023-2036. |
| | 155. | Wei, Y. et al. (2001). "Global Impact of *sdi*A Amplification Revealed by Comprehensive Gene Expression Profiling of *Escherichia coli*," *J. Bacteriol.* 183(7): 2265-2272. |
| | 156. | Weitz-Schmidt, G. et al. (2001). "Statins Selectively Inhibit Leukocyte Function Antigen-1 by Binding to a Novel Regulatory Integrin Site," *Nature Medicine* 7(6):687-692. |
| | 157. | Welsenbach, K. et al. (2002). "Small Molecule Inhibitors Induce Conformational Changes in the I Domain and the I-like Domain of Lymphocyte Function-Associated Antigen-1," *The Journal of Biological Chemistry* 277(12):10590-10598. |
| | 158. | Winn, M. et al. (2001). "Discovery of Novel p-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intercelular Adhesion Molecule-1 Interaction. 4. Structure-Activity Relationship of Substituents on the Benzene Ring of the Cinnamide," *J. Med. Chem.* 44:4393-4403. |
| | 159. | Yang, G.X. et al. (2002). "*N*-Tetrahydrofuroyl-(L)-Phenylalanine Derivatives as Potent VLA-4 Antagonists," *Bioorganic & Medicinal Chemistry Letters* 12:1497-1500. |
| | 160. | Young, K. et al. (1995). "The *envA* Permeability/Cell Division Gene of *Escherichia coli* Encodes the Second Enzyme of Lipid A Biosynthesis. UDP-3-*O*-(*R*-3-hydroxymyristoyl)-*N*-acetylglucosamine deacetylase," *J. Biol. Chem.* 270(51):30384-30391. |
| | 161. | Zimmerman, C.N. (1999). "Peptide and Peptidomimetic Inhibitors of VLA-4," *Expert Opinion on Therapeutic Patents* 9(2):129-133. |

| EXAMINER: | DATE CONSIDERED: |
|---|---|

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.